Our Research

Rhythm is advancing setmelanotide in a broad clinical development program that includes trials evaluating its efficacy and safety in a variety of melanocortin-4 receptor (MC4R) pathway variants.

Rhythm's research efforts include deepening the understanding of MC4R pathway-related rare genetic diseases of obesity through its DNA sequencing data streams.

To learn more about a Rhythm Pharmaceuticals clinical trial, please contact us at clinicaltrials@rhythmtx.com.

Key Research Articles Related to Setmelanotide

Recent Conference Presentations

Bardet-Biedl Syndrome

Phase 2 (Basket Trial) POMC/PCSK1/LEPR Heterozygous Deficiency, SRC1 Deficiency Obesity, and SH2B1 Deficiency Obesity

Uncovering Rare Obesity® Program (Genetic Testing Program in the United States)

Ongoing/Rhythm Pharmaceuticals Clinical Trials

You are now leaving Rhythm Medical Gateway. Links to all outside websites are provided as a convenience to our visitors and do not imply a recommendation by Rhythm Pharmaceuticals.

The information contained on this site is intended for US health care professionals only